NEEDHAM, Mass. — February 11, 2026 — Leads & Copy — Candel Therapeutics, Inc. (Nasdaq: CADL) announced that Francesca Barone, M.D., Ph.D., Candel’s Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit.
The summit is scheduled for February 17-19, 2026, in Boston, Massachusetts.
Dr. Barone is set to share insights from Candel’s HSV-based platform and the linoserpaturev (CAN-3110) program in recurrent high-grade glioma (rHGG) through workshop presentations and panel discussions. These sessions will focus on advancing biomarker-driven clinical development in glioblastoma.
The workshop panel, titled “Harnessing Omics Data & Molecular Subtyping to Inform Patient Stratification in Clinical & Translational Strategies in Glioblastoma Drug Development,” is scheduled for Tuesday, Feb. 17, 2026, at 8:00 a.m. ET.
The conference presentation, titled “Integration of Biomarkers & Imaging to Define Patient Response in a Phase I/II Clinical Trial,” is scheduled for Wednesday, Feb. 18, 2026, at 9:30 a.m. ET.
The panel discussion, titled “Driving the Use of Biomarker-Based Enrollment in GBM Trials to Accelerate Clinical Success & Improve Patient Outcomes,” is scheduled for Wednesday, Feb. 18, 2026, at 12:00 p.m. ET.
CAN-3110 is described as a first-in-class, replication-competent, next-generation oncolytic herpes simplex virus-1 (HSV-1) immunotherapy candidate designed for dual activity for oncolysis and immune activation in a single therapeutic.
In October 2023, the company announced the publication of results in Nature from an ongoing clinical trial, where linoserpaturev was reported to be generally well tolerated with no dose-limiting toxicity. The trial investigators observed improved median overall survival compared to historical controls after a single linoserpaturev injection in this therapy-resistant condition.
Candel and academic collaborators are supported by the Break Through Cancer foundation to evaluate the effects of repeated linoserpaturev injections in patients with recurrent glioblastoma in an expansion cohort from the phase 1b clinical trial.
In October 2025, Science Translational Medicine presented findings from the comprehensive analysis of 97 serial tumor biopsies collected from two patients treated with repeated administrations of linoserpaturev in arm C. Linoserpaturev previously received Fast Track Designation and Orphan Drug Designation for the treatment of recurrent HGG from the U.S. Food and Drug Administration (FDA).
Candel Therapeutics is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs.
Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA.
The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation for the treatment of PDAC.
Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent HGG. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Source: Candel Therapeutics, Inc.
